CVS Health is trading 10% down at $93.97 as investors focus on long-term insurance and cost concerns despite the company reporting a second-quarter earnings beat.
- CVS raised its full-year 2026 adjusted EPS guidance to $7.20–$7.35 following stronger-than-expected quarterly revenue and profit.
- Management highlighted a stabilizing Medicare benefit ratio and an improved outlook for cash flow generation.
- The stock decline suggests persistent market anxiety regarding rising medical costs and the long-term insurance landscape.